Tau imaging probe
An object of the present invention is to provide a probe for imaging a β-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R a and R b are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.
1. A compound of the formula (I):
wherein
A is
R 1 is halogen, a —C(═O)-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from NR a R b , halogen and a hydroxy group), a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), a —O-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), or
in which
R 4 and R 5 each independently represents hydrogen, a lower alkyl group or a cycloalkyl group, or R 4 , R 5 and the nitrogen atom to which they are attached are taken together to form a 3- to 8-membered nitrogen-containing aliphatic ring (one or more carbon atoms constituting the nitrogen-containing aliphatic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group),
or R 4 and the nitrogen atom to which it is attached are taken together with ring A to form a 8- to 1 6-membered nitrogen-containing fused bicyclic ring (one or more carbon atoms constituting the nitrogen-containing fused bicyclic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group) and R 5 represents hydrogen, a lower alkyl group or a cycloalkyl group,
in which the line, that the dotted line intersects, means a bond of the above general formula to the other structural moiety,
R 2 or R 3 each independently represents halogen, OH, COOH, SO 3 H, NO 2 , SH, NRaR b , a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group) or a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group), ring A is unsubstituted, or substituted with R 6 (in which R 6 is one or more substituents selected independently from halogen, OH, COOH, SO 3 H, NO 2 , SH, NRaR b , a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group) and a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group,
R a and R b each independently represents hydrogen or a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group),
m is an integer of 0 to 4,
n is an integer of 0 to 4 such that when m is 0 and n is 0, ring A is substituted with R 6 ,
wherein at least one of R 2 , R 3 and R 6 is a —O-lower alkyl group substituted with one hydroxy group and one halogen wherein at least one of R 2 , R 3 and R 4 is —O-lower alkyl group in the range of C1 to C5,
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound according to claim 1 , wherein R 1 is halogen, a —C(═O)-lower alkyl group (the alkyl group each independently may be substituted with NH 2 ), a lower alkyl group (the alkyl group each independently may be substituted with a hydroxy group), —O-lower alkyl group, or
in which
R 4 and R 5 each independently represents hydrogen or a lower alkyl group, or a pharmaceutically acceptable salt or solvate thereof.
3. The compound according to claim 1 , wherein at least one of R 2 , R 3 and R 6 is represented by:
or a pharmaceutically acceptable salt or solvate thereof.
4. The compound according to claim 1 , wherein at least one of R 2 , R 3 and R 6 is NR a R b , and R a and R b each independently represents hydrogen or an unsubstituted lower alkyl group, or a pharmaceutically acceptable salt or solvate thereof.
5. The compound according to claim 1 , wherein the compound is labeled, or a pharmaceutically acceptable salt or solvate thereof.
6. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof.
7. A composition for the diagnosis of a conformational disease, comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the conformational disease is selected from the group consisting of Alzheimer's disease, prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, spinal and bulbar atrophy, dentate-rubro-pallido-luysian atrophy, Spinocerebellar Degeneration, Machado-Joseph Disease, Amyophic Lateral Sclerosis (ALS), Down's syndrome, Pick's disease, FTDP-17 (Frontotemporal Dementia and Parkinsonism linked to Chromosome 17), LNTD (Limbic Neurofibrillary tangles Demetia), Sudanophiloc Leukodystrophy, progressive supranuclear palsy (PSP) and amyloidosis.
8. A kit for the diagnosis of a conformational disease, or detecting or staining a beta-sheet structure protein comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof as an essential ingredient, wherein the conformational disease is selected from the group consisting of Alzheimer's disease, prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, spinal and bulbar atrophy, dentate-rubro-pallido-luysian atrophy, Spinocerebellar Degeneration, Machado-Joseph Disease, Amyophic Lateral Sclerosis (ALS), Down's syndrome, Pick's disease, FTDP-17 (Frontotemporal Dementia and Parkinsonism linked to Chromosome 17), LNTD (Limbic Neurofibrillary tangles Demetia), Sudanophiloc Leukodystrophy, progressive supranuclear palsy (PSP) and amyloidosis.
9. A compound of the formula (I′):
wherein
A is
R 1 is halogen, a —C(═O)-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from NR a R b , halogen and a hydroxy group), a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), a —O-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), or
in which
R 4 and R 5 each independently represents hydrogen, a lower alkyl group or a cycloalkyl group, or R 4 , R 5 and the nitrogen atom to which they are attached are taken together to form a 3- to 8-membered nitrogen-containing aliphatic ring (one or more carbon atoms constituting the nitrogen-containing aliphatic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group),
or R 4 and the nitrogen atom to which it is attached are taken together with ring A to form a 8- to 16-membered nitrogen-containing fused bicyclic ring (one or more carbon atoms constituting the nitrogen-containing fused bicyclic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group) and R 5 represents hydrogen, a lower alkyl group or a cycloalkyl group, in which the line, that the dotted line intersects, means a bond of the above general formula to the other structural moiety,
R 2 or R 3 each independently may be substituted with halogen, OH, COOH, SO 3 H, NO 2 , SH, NR a R b , a lower alkyl group (the lower alkyl group each independently may be substituted with one or more substituents selected from a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy halogen and a hydroxy group) or a —O-lower alkyl group (the lower alkyl group is substituted with a p-toluenesulfonyloxy group, a methanesulfonyloxy group, trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy, and also may be substituted with-a halogen and a hydroxy group),
ring A is unsubstituted or substituted with R 6 (in which R 6 is one or more substituents selected independently from halogen, OH, COOH, SO 3 H, NO 2 , SH, NR a R b , a lower alkyl group (the lower alkyl group each independently may be substituted with one or more substituents selected from a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy, halogen and a hydroxy group) and an —O-lower alkyl group (the lower alkyl group each independently may be substituted with one or more substituents selected from a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy, halogen and a hydroxy group)),
R a and R b independently represents hydrogen or a lower alkyl group (the alkyl group and the lower alkyl group each independently may be substituted with one or more substituents selected from a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy, halogen and a hydroxy group),
m is an integer of 0 to 4, and
n is an integer of 0 to 4 such that when m is 0 and n is 0, ring A is substituted with R 6 ,
provided that at least one of R 2 , R 3 and R 6 represents an —O-lower alkyl group in the range of C1 to C5 (the lower alkyl group is substituted with a p-toluenesulfonyloxy group (tosyloxy group, TsO), a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group or a 2-tetrahydropyranyloxy (OTHP), and may also be substituted with one or more substituents selected from halogen and a hydroxy group), wherein at least one of R 2 , R 3 and R 6 is an -O- lower alkyl group in the range of C1 to C5, or a pharmaceutically acceptable salt or solvate thereof.
10. The compound according to claim 9 , wherein at least one of R 2 , R 3 and R 6 is a group of the formula:
11. A kit for producing the labeled compound according to claim 5 , or a pharmaceutically acceptable salt or solvate thereof, said kit comprising:
the compound according to claim 9 , or a pharmaceutically acceptable salt or solvate thereof,
a labeling agent, and
optionally, instructions for carrying out labeling.
12. A compound of the formula (I″):
wherein
A is
R 1 is
in which R 4 and R 5 each independently represents hydrogen, a lower alkyl group,
R 2 or R 3 each independently represents a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group), ring A is unsubstituted, or substituted with R 6 (in which R 6 is one or more substituents selected independently from a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group)),
m is an integer of 0 to 4,
n is an integer of 0 to 4 such that when m is 0 and n is 0, ring A is substituted with R 6 ,
wherein R 2 , R 3 and R 6 each represents a —O-lower alkyl group in the range of C1 C5 substituted with one hydroxy group and one halogen, wherein at least one of R 2 , R 3 and R 6 is an -O- lower alkyl group in the range of C1 to C5,
or a pharmaceutically acceptable salt or solvate thereof.
13. The compound according to claim 12 , wherein the compound is labeled, or a pharmaceutically acceptable salt or solvate thereof.
14. A pharmaceutical composition comprising the compound according to claim 12 , or a pharmaceutically acceptable salt or solvate thereof.
15. A composition for the diagnosis of a conformational disease, comprising the compound according to claim 12 , or a pharmaceutically acceptable salt or solvate thereof, wherein the conformational disease is selected from the group consisting of Alzheimer's disease, prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, spinal and bulbar atrophy, dentate-rubro-pallido-luysian atrophy, Spinocerebellar Degeneration, Machado-Joseph Disease, Amyophic Lateral Sclerosis (ALS), Down's syndrome, Pick's disease, FTDP-17 (Frontotemporal Dementia and Parkinsonism linked to Chromosome 17), LNTD (Limbic Neurofibrillary tangles Demetia), Sudanophiloc Leukodystrophy, progressive supranuclear palsy (PSP) and amyloidosis. pharmaceutically acceptable salt or solvate thereof.
16. A kit for the diagnosis of a conformational disease, or detecting or staining a beta-sheet structure protein comprising the compound according to claim 12 , or a pharmaceutically acceptable salt or solvate thereof as an essential ingredient, wherein the conformational disease is selected from the group consisting of Alzheimer's disease, prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, spinal and bulbar atrophy, dentate-rubro-pallido-luysian atrophy, Spinocerebellar Degeneration, Machado-Joseph Disease, Amyophic Lateral Sclerosis (ALS), Down's syndrome, Pick's disease, FTDP-17 (Frontotemporal Dementia and Parkinsonism linked to Chromosome 17), LNTD (Limbic Neurofibrillary tangles Demetia), Sudanophiloc Leukodystrophy, progressive supranuclear palsy (PSP) and amyloidosis.
17. The compound according to claim 12 , wherein the compound comprises: